Clinical Trial Update: A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors [Phase 1]

View source ↗

Summary

Phase 1 study assessing a subcutaneous formulation of TQB2934 for injection in subjects with malignant plasma cell tumors, including multiple myeloma, which is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TQB2934

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING